World Allergy Organization Anaphylaxis Guidelines: 2013 update of the evidence base
Abstract
The World Allergy Organization (WAO) Guidelines for the assessment and management of anaphylaxis are a widely disseminated and used resource for information about anaphylaxis. They focus on patients at risk, triggers, clinical diagnosis, treatment in health care settings, self-treatment in the community, and prevention of recurrences. Their unique strengths include a global perspective informed by prior research on the global availability of essentials for anaphylaxis assessment and management and a global agenda for anaphylaxis research. Additionally, detailed colored illustrations are linked to key concepts in the text [Simons et al.: J Allergy Clin Immunol 2011;127:593.e1-e22]. The recommendations in the original WAO Anaphylaxis Guidelines for management of anaphylaxis in health care settings and community settings were based on evidence published in peer-reviewed, indexed medical journals to the end of 2010. These recommendations remain unchanged and clinically relevant. An update of the evidence base was published in 2012 [Simons et al.: Curr Opin Allergy Clin Immunol 2012;12:389-399]. In 2012 and early 2013, major advances were reported in the following areas: further characterization of patient phenotypes; development of in vitro tests (for some allergens) that help distinguish clinical risk of anaphylaxis from asymptomatic sensitization; epinephrine (adrenaline) research, including studies of a new epinephrine auto-injector for use in community settings, and randomized controlled trials of immunotherapy to prevent food-induced anaphylaxis. Despite these advances, the need for additional prospective studies, including randomized controlled trials of interventions in anaphylaxis is increasingly apparent. This 2013 Update highlights publications from 2012 and 2013 that further contribute to the evidence base for the recommendations made in the original WAO Anaphylaxis Guidelines. Ideally, it should be used in conjunction with these Guidelines and with the 2012 Guidelines Update.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Severe MCA (anaphylaxis) often involves two or more organ systems, although it may present primarily as hypotension leading to anaphylactic shock.
“Independent of the clinical diagnosis, severe MCA (anaphylaxis) often involves two or more organ systems, although it may present primarily as hypotension leading to anaphylactic shock.”
From Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review (2021) · cites this paper as [21]
Cites
Relationship between red meat allergy and sensitization to gelatin and galactose-α-1,3-galactose
Mullins, R. J., James, H., Platts-Mills, T. A. E., & Commins, S. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.02.038 · Cited by 260 · see citing works
Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis
Vadas, P., Perelman, B., & Liss, G. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.08.016 · Cited by 223 · see citing works
Sala-Cunill, A., Cardona, V., Labrador-Horrillo, M., Luengo, O., Esteso, O., Garriga, T., Vicario, M., & Guilarte, M. (2013) · International Archives of Allergy and Immunology · doi:10.1159/000339749 · Cited by 179 · see citing works
Mast cell activation syndromes: definition and classification
Valent, P. (2013) · Allergy · doi:10.1111/all.12126 · Cited by 120 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Human mast cell tryptase in biology and medicine
Vitte, J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2014.04.001 · Cited by 152 · see citing works
Tryptase levels in children presenting with anaphylaxis: Temporal trends and associated factors
De Schryver, S., Halbrich, M., Clarke, A., La Vieille, S., Eisman, H., Alizadehfar, R., Joseph, L., Morris, J., & Ben-Shoshan, M. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2015.09.001 · Cited by 96 · see citing works
Gülen, T., Akin, C., Bonadonna, P., Siebenhaar, F., Broesby-Olsen, S., Brockow, K., Niedoszytko, M., Nedoszytko, B., Oude Elberink, H. N. G., Butterfield, J. H., et al. (2021) · The Journal of Allergy and Clinical Immunology: In Practice · doi:10.1016/j.jaip.2021.06.011 · Cited by 83 · see citing works
“Independent of the clinical diagnosis, severe MCA (anaphylaxis) often involves two or more organ systems, although it may present primarily as hypotension leading to anaphylactic shock.(20,21) In patients with systemic mastocytosis (SM), the risk for developing severe or even life-threatening anaphylaxis is high, espe…”
BackgroundAnaphylaxis as a clinical manifestation of clonal mast cell disorders
Matito, A., Alvarez-Twose, I., Morgado, J. M., Sánchez-Muñoz, L., Orfao, A., & Escribano, L. (2014) · Current Allergy and Asthma Reports · doi:10.1007/s11882-014-0450-8 · Cited by 51 · see citing works
Multinational experience with hypersensitivity drug reactions in Latin America.
Jares, E. J., Sánchez-Borges, M., Cardona-Villa, R., Ensina, L. F., Arias-Cruz, A., Gómez, M., Barayazarra, S., Bernstein, J. A., Serrano, C. D., Cuello, M. N., et al. (2014) · Annals of Allergy, Asthma & Immunology · doi:10.1016/j.anai.2014.06.019 · Cited by 48 · see citing works
- Authors
- Simons, F. E. R., Ardusso, L. R. F., Dimov, V., Ebisawa, M., El-Gamal, Y. M., Lockey, R. F., Sanchez-Borges, M., Senna, G. E., Sheikh, A., Thong, B. Y., Worm, M., & for the World Allergy Organization
- Affiliations
- University of Manitoba (CA)
- National University of Rosario (AR)
- University of Chicago (US)
- National Sagamihara Hospital (JP)
- University of South Florida (US)
- University of Edinburgh (GB)
- Tan Tock Seng Hospital (SG)
- Charité – Universitätsmedizin Berlin (DE)
- ORCID
- Venue
- International Archives of Allergy and Immunology
- Publisher
- S. Karger AG
- Published
- 2013
- Volume
- 162
- Issue
- 3
- Pages
- 193-204
- ISSN
- 1018-2438 (ISSN-L)
- 1423-0097
- OpenAlex
- W2128440872
- Cited by
- 269
- References
- 4
- Citations by year
- 2026: 4 · 2025: 3 · 2024: 9 · 2023: 9 · 2022: 12 · 2021: 23 · 2020: 26 · 2019: 23 · 2018: 21 · 2017: 29 · 2016: 30 · 2015: 38 · 2014: 39 · 2013: 2
- FWCI
- 5.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Archives of Allergy and Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Immunology and Allergy › Food Allergy and Anaphylaxis Research
- Health Sciences › Medicine › Pharmacology › Drug-Induced Adverse Reactions
- Health Sciences › Medicine › Immunology and Allergy › Allergic Rhinitis and Sensitization
- Keywords
- anaphylaxis, anaphylaxis management, epinephrine auto-injector, food-induced anaphylaxis, allergen immunotherapy, in vitro allergy testing, anaphylaxis triggers
- MeSH terms
- Anaphylaxis, Humans, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review